Efficacy analysis of vincristine, adriamycin, dexamethasone chemotherapy regimen combined with thalidomide in the treatment of multiple myeloma nephropathy and its impact on renal function factors.

Myeloma nephropathy is a rare but challenging disease. This study aimed to evaluate the efficacy and renal functional outcomes of the VAD chemotherapy regimen and thalidomide treatment for myeloma nephropathy. From August 2022 to December 2023, a total of 94 patients were admitted to People's Hospital of Shangrao City. Patients were randomly assigned to Group C (VAD chemotherapy) and Group O (VAD chemotherapy plus thalidomide). Comparisons of renal function, treatment outcomes and patient characteristics indicated that disease control and overall efficacy were significantly better in Group O (P<0.05). Compared with Group C, Group O also had greater reductions in serum creatinine, blood urea nitrogen, retinol-binding protein, M-protein, bone marrow plasma cells, and 24-hour proteinuria (P<0.05). Hemoglobin levels were significantly higher in Group O (P<0.05), and adverse reactions were significantly lower (P<0.05). The combination of VAD chemotherapy and thalidomide improved the therapeutic effects and renal function in myeloma nephropathy, supporting further exploration of this therapy.